Paper39403308
Non-Alcoholic Steatohepatitis Patient Characterization and Real-World Management Approaches in Italy.
Bugianesi E and 7 others. Pragmat Obs Res, 2024. Cited by 1 paper, by iCite.
Cite this record
ConductScience Library. Non-Alcoholic Steatohepatitis Patient Characterization and Real-World Management Approaches in Italy. Papers, record 39403308. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/39403308
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Non-Alcoholic Steatohepatitis Patient Characterization and Real-World Management Approaches in Italy.
- PubMed
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
References47
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 32598051 | Clinical assessment for high-risk patients with non-alcoholic fatty liver disease in primary care and diabetology practices. | Aliment Pharmacol Ther | 2020 | https://conductscience.org/library/papers/32598051 | PubMed |
| 2 | 31341444 | Non-Alcoholic Fatty Liver Disease, an Overview. | Integr Med (Encinitas) | 2019 | https://conductscience.org/library/papers/31341444 | PubMed |
| 3 | 3280274 | Is hepatic ultrasonography a valid alternative tool to liver biopsy? Report on 507 cases studied with both techniques. | Dig Dis Sci | 1988 | https://conductscience.org/library/papers/3280274 | PubMed |
| 4 | 12879405 | Statin therapy for the treatment of diabetic dyslipidemia. | Diabetes Metab Res Rev | 2003 | https://conductscience.org/library/papers/12879405 | PubMed |
| 5 | 18826746 | Real-world physician and patient behaviour across countries: Disease-Specific Programmes - a means to understand. | Curr Med Res Opin | 2008 | https://conductscience.org/library/papers/18826746 | PubMed |
| 6 | 30875495 | Statins and nonalcoholic fatty liver disease in the era of precision medicine: More friends than foes. | Atherosclerosis | 2019 | https://conductscience.org/library/papers/30875495 | PubMed |
| 7 | 30547371 | Understanding Patient Preferences and Unmet Needs in Non-alcoholic Steatohepatitis (NASH): Insights from a Qualitative Online Bulletin Board Study. | Adv Ther | 2019 | https://conductscience.org/library/papers/30547371 | PubMed |
| 8 | 25873207 | Comparative diagnostic accuracy of magnetic resonance elastography vs. eight clinical prediction rules for non-invasive diagnosis of advanced fibrosis in biopsy-proven non-alcoholic fatty liver disease: a prospective study. | Aliment Pharmacol Ther | 2015 | https://conductscience.org/library/papers/25873207 | PubMed |
| 9 | 11296698 | Imaging of hepatic steatosis. | Semin Liver Dis | 2001 | https://conductscience.org/library/papers/11296698 | PubMed |
| 10 | 29886156 | Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016-2030. | J Hepatol | 2018 | https://conductscience.org/library/papers/29886156 | PubMed |
| 11 | 34133035 | Statin liver safety in non-alcoholic fatty liver disease: A systematic review and metanalysis. | Br J Clin Pharmacol | 2022 | https://conductscience.org/library/papers/34133035 | PubMed |
| 12 | 25312733 | Adverse effects of statins - myths and reality. | Curr Pharm Des | 2015 | https://conductscience.org/library/papers/25312733 | PubMed |
| 13 | 36626630 | The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review. | Hepatology | 2023 | https://conductscience.org/library/papers/36626630 | PubMed |
| 14 | 24374462 | Statins for non-alcoholic fatty liver disease and non-alcoholic steatohepatitis. | Cochrane Database Syst Rev | 2013 | https://conductscience.org/library/papers/24374462 | PubMed |
| 15 | 27843332 | Trends in medication use in patients with type 2 diabetes mellitus: a long-term view of real-world treatment between 2000 and 2015. | Diabetes Metab Syndr Obes | 2016 | https://conductscience.org/library/papers/27843332 | PubMed |
| 16 | 36675217 | GLP-1 Receptor Agonists in Non-Alcoholic Fatty Liver Disease: Current Evidence and Future Perspectives. | Int J Mol Sci | 2023 | https://conductscience.org/library/papers/36675217 | PubMed |
| 17 | 30924946 | Sex Differences in Nonalcoholic Fatty Liver Disease: State of the Art and Identification of Research Gaps. | Hepatology | 2019 | https://conductscience.org/library/papers/30924946 | PubMed |
| 18 | 30839334 | Implementation of Clinical Practice Guidelines in the Health Care Setting: A Concept Analysis. | ANS Adv Nurs Sci | 2019 | https://conductscience.org/library/papers/30839334 | PubMed |
| 19 | 34588764 | Non-Alcoholic Steatohepatitis (NASH) - A Review of a Crowded Clinical Landscape, Driven by a Complex Disease. | Drug Des Devel Ther | 2021 | https://conductscience.org/library/papers/34588764 | PubMed |
| 20 | 30819364 | Nonalcoholic Fatty Liver Disease and the Heart: JACC State-of-the-Art Review. | J Am Coll Cardiol | 2019 | https://conductscience.org/library/papers/30819364 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Cited by
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/39403308
GET https://conductscience.org/api/papers/v1/39403308/references?page=2